AMENDMENTS TO THE CLAIMS

This listing of claims will replace all prior versions and listings of claims in the application:

LISTING OF CLAIMS:

1. (currently amended): An ~~oncogene~~ isolated polynucleotide ~~derived from human involving development of cervical cancer,~~ comprising a nucleotide sequence encoding the polypeptide represented by ~~an amino acid sequence of~~ SEQ. ID. No.1.

2. (currently amended): The polynucleotide of ~~as claimed in~~ Claim 1 ~~wherein~~ comprising the nucleotide sequence set forth in ~~encoding the amino acid sequence of SEQ. ID. No.1 is a nucleotide sequence of~~ SEQ. ID. No.2.

3. (currently amended): A recombinant polypeptide or its salts, comprising ~~an~~ the amino acid sequence of SEQ. ID. No.1 ~~or a partial amino acid sequence of the amino acid sequence~~.

4. (original): A recombinant oncogenic protein comprising an amino acid sequence of SEQ. ID. No.1.

5. (currently amended): A recombinant vector comprising a polynucleotide ~~encoding the recombinant peptide as claimed in Claim 3~~ of Claim 1 or Claim 2.

6. (canceled): A recombinant vector comprising the polynucleotide as claimed in Claim 1 or 2.

7. (currently amended): A transformed cell produced by transforming a host cell ~~using~~ with the recombinant vector ~~as claimed in~~ of Claim 5.

8. (canceled): A transformed cell produced by transforming a host cell using the recombinant vector as claimed in Claim 6.

9. (currently amended): A process for producing the recombinant polypeptide ~~as claimed in~~ of Claim 3 or its salts comprising the steps of:

transforming a host cell with a recombinant vector comprising a polynucleotide encoding the polypeptide represented by SEQ. ID. No. 1, thereby creating a transformed cell;

culturing the transformed cell ~~as claimed in Claim 7 to allow~~ whereby the transformed cell ~~to~~ produces ~~the~~said ~~recombinant~~ polypeptide ~~as claimed in Claim 3~~; and

collecting ~~the~~ said recombinant polypeptide ~~produced~~ from the culture.

10. (currently amended): A process for producing the recombinant oncogenic protein of ~~as claimed in~~ Claim 4 comprising the steps of:

transforming a host cell with a recombinant vector comprising a polynucleotide encoding an oncogenic protein with the amino acid sequence of SEQ. ID. No. 1, thereby creating a transformed cell;

culturing the transformed cell ~~as claimed in Claim 8 to allow~~ whereby the transformed cell ~~to~~ produces ~~the~~said recombinant oncogenic protein ~~as claimed in Claim 4~~; and

collecting ~~the~~ said recombinant oncogenic protein ~~produced~~ from the culture.

11. (currently amended): An antibody ~~which is a specific antibody~~ generated using the recombinant polypeptide of ~~as claimed in~~ Claim 3 as an immunogen.

12. (currently amended): The antibody ~~as claimed in~~ of Claim 11, wherein ~~the~~ said antibody is reactive to an epitope of said recombinant polypeptide, and wherein said epitope is

within ~~partial~~ amino acids ~~sequence of~~ 623 to 1185 of said recombinant polypeptide ~~region of the amino acid sequence of SEQ. ID. No.1~~.

13. (currently amended): ~~An antibody reagent~~ kit for an antigen-antibody reaction comprising the antibody ~~as claimed in~~ of Claim 11, wherein said antibody detects ~~available for detecting~~ an oncogenic protein comprising the amino acid sequence of SEQ. ID. No.1 ~~or a peptide fragment derived from the oncogenic protein~~.

14. (currently amended): ~~A diagnosis~~ The kit ~~being usable~~ of claim 13 for detection of an oncogenic protein comprising the amino acid sequence of SEQ. ID. No.1 or a peptide fragment derived from said ~~the~~ oncogenic protein, wherein said peptide fragment contains the epitope recognized by said antibody ~~by means of an antigen-antibody reaction, comprising the antibody as claimed in Claim 11.~~

15. (currently amended): ~~An antisense~~ polynucleotide comprising a ~~complementary nucleotide sequence to a partial~~ nucleotide sequence complementary to ~~of the~~ a nucleotide sequence of SEQ. ID. No.2, wherein ~~which is a DNA fragment~~ said polynucleotide ~~having~~ has at least a length ~~selected from the region~~ of 15 to 300 bases.

16. (currently amended): A ~~probe~~ hybridization kit ~~available for detecting an mRNA comprising the nucleotide sequence of SEQ. ID. No.2, its partial nucleotide sequence or cDNA prepared by the mRNA~~, comprising the ~~antisense~~ polynucleotide ~~as claimed in~~ of Claim 15 ~~as the DNA probe therein~~.

17. (currently amended): A ~~diagnosis~~ kit ~~available~~ for detecting expression of mRNA ~~comprising the nucleotide sequence of SEQ. ID. No.2,~~ which is translated into an oncogenic

protein comprising the amino acid sequence of SEQ. ID. No.1~~, by means of a probe hybridization method~~, comprising the ~~antisense~~ polynucleotide of~~as claimed in~~ Claim 15 ~~as the hybridization probe~~.

18. (currently amended): A primer pair for PCR amplification of cDNA comprising the nucleotide sequence of SEQ. ID. No.2, consisting of the following paired primers ~~of~~:

a nucleotide sequence :

5'-TTGGATCCATGACATCCAGATTTGGGAAAACATACAGTAGG-3'; and

a nucleotide sequence :

5'-TTGAATTCCTAGCAATGTTCCAAATATTCAATCACTCTAGA-3'.

19. (currently amended): A primer pair for PCR amplifyication~~ng~~ of a partial ~~chain in~~ cDNA comprising ~~the~~ a nucleotide sequence of SEQ. ID. No.2, consisting of the following paired primers ~~of~~:

5'-GAATTCATAGGCACAGCGCTGAACTGTGTG-3'; and

5'-TTGAATTCCTAGCAATGTTCCAAATATTCA-3'.

20. (currently amended): A double strand of short-chain interfering RNA (siRNA) capable of inhibiting expression of a target mRNA ~~comprising the nucleotide sequence of SEQ. ID No. 2~~ in a cervical cancer cell, wherein the siRNA has a nucleotide sequence:

CGGACTACCCTTAGCACAA.

21. (currently amended): A pharmaceutical composition for inhibiting expression of a target mRNA ~~comprising the nucleotide sequence of SEQ. ID. No.2~~ in a cervical cancer cell to

arrest growth of saidthe carcinoma cell, comprising the siRNAdouble strand of short chain interfering RNA as claimed in of Claim 20.